Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

British journal of cancer - 15 Sept 2009

Chua W, Goldstein D, Lee C K, Dhillon H, Michael M, Mitchell P, Clarke S J, Iacopetta B

Abstract excerpt

BACKGROUND: To investigate three genetic alterations (TP53 mutation, Kras mutation and microsatellite instability (MSI)) and three polymorphisms (methylene tetrahydrofolate reductase (MTHFR) C677T, excision repair cross complementing group 1 (ERCC1)-118 and X-ray repair cross complementing group 1 (XRCC1)-399) for their ability to predict response, survival and toxicity to FOLFOX first line chemotherapy in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endonucleases
Share to Fluorouracil
Share to Leucovorin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Organoplatinum Compounds

Share to Proportional Hazards Models

Share to ras Proteins

Share to X-ray Repair Cross Complementing Protein 1

Source

Open in PubMed Open full text

Identifiers

PMID: 19672255
DOI: 10.1038/sj.bjc.6605239
PMCID: PMC2743363

Genes

ERCC1
MTHFR
XRCC1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.PMID 19672255Read ↗

Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapySemantic proximity Read ↗

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patientsSemantic proximity Read ↗

The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.Semantic proximity Read ↗

Use of a Comprehensive Panel of Biomarkers to Predict Response to a Fluorouracil–Oxaliplatin Regimen in Patients with Metastatic Colorectal CancerSemantic proximity Read ↗

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.Semantic proximity Read ↗

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Semantic proximity Read ↗

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.Semantic proximity Read ↗

MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.Semantic proximity Read ↗

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant ChemotherapySemantic proximity Read ↗

Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patientsSemantic proximity Read ↗

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.